...
首页> 外文期刊>Medical science monitor : >Management of hyperlipidemia: new LDL-C targets for persons at high-risk forcardiovascular events.
【24h】

Management of hyperlipidemia: new LDL-C targets for persons at high-risk forcardiovascular events.

机译:高脂血症的管理:针对高危心血管事件患者的新LDL-C靶标。

获取原文

摘要

Coronary heart disease (CHD) remains the leading cause of mortality inthe United States, and is associated with significant health care costs. Current evidence overwhelminglyconfirms the role of low-density lipoprotein cholesterol (LDL-C) in the pathogenesis of atherosclerosisand the risk of CHD events. The approach to the management of hyperlipidemia has evolved dramaticallyover the past decade. Randomized clinical trails have provided strong evidence that lowering plasma cholesterolwith statins reduces the risk of cardiovascular events, particularly in high-risk patients, irrespectiveof baseline cholesterol levels. The National Cholesterol Education Program (NCEP) report was releasedin July 2004. The report examined the results of recently concluded clinical trials and provided consensusrecommendations on the management of hyperlipidemia. The report expands on the core content of the previouslypublished guidelines. However, it is by far the most aggressive approach to date for reducing CHD risk.A focal element of the report is the modification of LDL-C goal in high-risk patients to
机译:冠心病(CHD)仍然是美国死亡的主要原因,并且与高昂的医疗保健费用相关。当前的证据绝大多数证实了低密度脂蛋白胆固醇(LDL-C)在动脉粥样硬化的发病机理和冠心病事件风险中的作用。在过去的十年中,高脂血症的管理方法已经发生了巨大的变化。随机临床试验提供了有力的证据表明,使用他汀类药物降低血浆胆固醇可降低发生心血管事件的风险,特别是在高危患者中,无论基线胆固醇水平如何。国家胆固醇教育计划(NCEP)报告于2004年7月发布。该报告审查了最近结束的临床试验结果,并就高脂血症的治疗提出了共识性建议。该报告扩展了先前发布的指南的核心内容。然而,这是迄今为止降低冠心病风险最积极的方法。该报告的重点是将高危患者的LDL-C目标调整为

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号